Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as the reason for the sudden closure. A board representing the founding…
With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart…
Guideline-Recommended, Yet Unavailable: Addressing Choline Deficiency in Patients Dependent on Parenteral Nutrition By Jacqueline Zummo, PhD, MPH Co-founder, Chief Scientific and Operations Officer, Protara Therapeutics Choline is an essential quaternary…
Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery…
Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated steatohepatitis (MASH) combo. The…
The Fierce network just got stronger. Questex has acquired The Conference Forum and Versalinx Global Events, two highly respected organizers known for convening the leaders shaping clinical innovation, competitive intelligence,…
After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease. Harmony announced…
Pfizer may have launched a multifront legal battle to prevent Metsera from heading to Novo Nordisk, but, behind the scenes, the U.S. pharma has shown some willingness to rework its…
Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an…
It’s all change at Prelude Therapeutics. The precision oncology biotech is waving goodbye to its chief medical officer, pausing work on SMARCA2 degraders and selling a licensing option to Incyte…